# Meissa Vaccines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/meissa-vaccines

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: http://www.meissavaccines.com
- Total disclosed funding: $14M
- Latest round: Series A (Sep 17, 2019)
- Investors on record: 2

## About

Meissa Vaccines, Inc. is focused on developing innovative vaccine solutions targeting respiratory viruses, particularly for public health challenges. Their proprietary vaccine candidates aim to enhance efficacy and safety.Founded in 2014, Meissa Vaccines, Inc. operates from Redwood City, US, specializing in vaccine development. The company has raised a total of USD 13.92 mn through 3 deals, with the most recent being a Series A round on September 17, 2019, led by 5Y Capital. The company is co-founded and led by Martin Moore and Frank Glavin, who have experience in the biopharmaceutical sector.Meissa Vaccines specializes in the development of innovative vaccine solutions aimed at addressing global public health challenges. The company’s core offerings are primarily centered around its proprietary vaccine candidates designed to combat respiratory viruses, with a particular focus on respiratory syncytial virus (RSV). The vaccines are engineered to enhance efficacy and safety profiles, providing significant value to healthcare providers and high-risk populations. Meissa Vaccines serves a diverse client base, including hospitals, healthcare systems, and public health organizations, primarily within North America and Europe, to improve immunization rates and reduce respiratory disease burdens.The revenue model of Meissa Vaccines is structured around strategic partnerships and B2B transactions with healthcare providers and institutions. The company engages directly with clients through contractual agreements for bulk purchases of its vaccine products. Meissa Vaccines' flagship products are competitively priced in alignment with industry standards, fostering accessibility while supporting sustainability for ongoing research and development efforts. Revenue generation is closely tied to successful trials and market adoption, with collaborations enhancing its financial performance through shared expertise.Meissa Vaccines plans to leverage its recent Series A funding of USD 13.92 mn raised in September 2019 to support the development of new vaccine candidates and expand its market reach. The company aims to launch additional vaccine products targeting respiratory viruses within the next few years, and is exploring expansion into European and Asian markets to increase accessibility. These initiatives are designed to enhance its growth trajectory and address the identified public health challenges in these regions.

## Funding rounds

- Series A, Sep 17, 2019, $14M — 5Y Capital
- Seed, Aug 3, 2017 — FundRx

## Investors

- FundRx (https://capitalatlas.ai/funds/fundrx) — Seed
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A